Codexis (CDXS) Stock Price, News & Analysis

Company Overview

Codexis, Inc. is a biotechnology company that develops enzymes and enzyme-based technologies for pharmaceutical, chemical and other industrial applications. Its platform is designed to improve naturally occurring enzymes through protein engineering, helping customers develop more efficient, selective and sustainable biocatalytic processes.

The company’s core technology, CodeEvolver, uses directed evolution and computational methods to create or optimize enzymes for specific manufacturing and commercial needs. Codexis provides engineered enzymes, biocatalyst development services and related process-development support, with applications that include the production of active pharmaceutical ingredients, specialty chemicals and other high-value products.

Founded in 2002 and headquartered in Redwood City, California, Codexis serves customers and partners internationally through direct commercial activities, collaborations and licensing arrangements. The company is led by Stephen D. Dilly, M.D., Ph.D., who became chief executive officer in 2023. Codexis trades on the Nasdaq under the symbol CDXS.

Key Stats

• Today's Range: $1.32 to $1.40
• 50-Day Range: $1.32 to $2.21
• 52-Week Range: $0.96 to $2.98
• Volume: 464,301 shs
• Average Volume: 858,386 shs
• Market Capitalization: $144.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Hold

Codexis Stock Analysis - MarketRank™

Codexis scored higher than 51% of companies evaluated by MarketBeat, and ranked 482nd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Codexis has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Codexis has a consensus price target of $6.50, representing about 392.4% upside from its current price of $1.32.

Amount of Analyst Coverage

Codexis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Codexis are expected to grow in the coming year, from ($0.37) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Codexis is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Codexis is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Codexis has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.81% of the float of Codexis has been sold short.

Short Interest Ratio / Days to Cover

Codexis has a short interest ratio ("days to cover") of 5.74.

Change versus previous month

Short interest in Codexis has recently increased by 4.59%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Codexis does not currently pay a dividend.

Dividend Growth

Codexis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.18

News Sentiment

Codexis has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Codexis this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Codexis insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.50% of the stock of Codexis is held by insiders.

Percentage Held by Institutions

78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:CDXS
• CIK: 1200375
• Web: www.codexis.com
• Phone: (650) 421-8100
• Fax: 650-421-8102
• Employees: 146
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Codexis: $6.50
• High Price Target: $8.00
• Low Price Target: $5.00
• Potential Upside/Downside: +392.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.97 million
• Net Margins: -39.55%
• Pretax Margin: -39.46%
• Return on Equity: -74.36%
• Return on Assets: -23.58%

Debt

• Debt-to-Equity Ratio: 1.03
• Current Ratio: 3.06
• Quick Ratio: 2.99

Sales & Book Value

• Annual Sales: $77.68 million
• Price / Sales: 1.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.56 per share
• Price / Book: 2.36

Miscellaneous

• Outstanding Shares: 109,506,000
• Free Float: 105,673,000
• Market Cap: $144.55 million
• Optionable: Optionable
• Beta: 2.52